Efficacy of intranasal administration of neostigmine in myasthenic patients

J Neurol. 1992 Mar;239(3):165-9. doi: 10.1007/BF00833919.

Abstract

The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Intranasal
  • Aerosols
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / physiopathology
  • Drug Administration Schedule
  • Drug Evaluation
  • Humans
  • Injections, Intravenous
  • Muscles / physiopathology
  • Myasthenia Gravis / drug therapy*
  • Myasthenia Gravis / physiopathology
  • Neostigmine / administration & dosage
  • Neostigmine / therapeutic use*
  • Pilot Projects
  • Pyridostigmine Bromide / therapeutic use
  • Severity of Illness Index

Substances

  • Aerosols
  • Neostigmine
  • Pyridostigmine Bromide